Pharmaxis enters new quarter positioned for growth
The company finished the June quarter with $21.5 million in cash and is expecting more milestone payments this year.
Company
Syntara Ltd
ASX:PXS
Syntara Ltd is a clinical-stage drug development company focused on the development of novel therapeutics aimed at correcting extracellular matrix (ECM) dysfunction. This will lead to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
175 stories · page 7 of 9
Pharmaxis meets primary endpoint of Phase 3 trial of Bronchitol®
Pharmaxis has partnered its work on Bronchitol for the U.S. with Chiesi Group.
Pharmaxis appoints highly-experienced Dr Kathleen Metters to the board
Pharmaxis held a $25.5 million cash balance at the end of March.
Pharmaxis shares close higher on new cash payment
Pharmaxis is an Australian pharmaceutical research company.
Pharmaxis is now expecting a further cash injection
Payments of circa A$42 million are expected this year.
Pharmaxis 'extremely pleased' following supply agreement with Chiesi Farmaceutici SpA
The agreement is for the commercialisation of Bronchitol®.
Pharmaxis approaching three key potential share price drivers
The June quarter will keep investors leveraged to valuable news flow.
Pharmaxis’ substantial shareholders increase stakes
Today and yesterday, two substantial holders have increased their stakes.
Pharmaxis completes treatment phase in clinical trial for U.S. market
Pharmaxis' partner has funded US$22 million of the expected US$26 million trial cost.
Admedus appoints Simon Buckingham to board
Buckingham has more than 25 years’ experience in the global pharmaceutical industry.
Pharmaxis enters 2017 cashed up as shares strengthen
Pharmaxis is becoming a more enticing target for drug acquisition and partnerships.
Pharmaxis on track for multi-million euro milestone payment
The commencement of the trial will trigger a milestone payment.
Pharmaxis chairman buys shares on market
Pharmaxis (ASX:PXS) chairman, Malcolm McComas has acquired 200,000 shares on market for a total cost of $54,167.
Pharmaxis Ltd looking like an enticing target for big pharma
Mergers and acquisitions are increasing in the fibrosis and NASH space.
Pharmaxis Ltd in research collaboration with prestigious institute
Gary Phillips, CEO, commented: "This research will bring together the acknowledged expertise of the Woolcock Institute and Pharmaxis in the field of cystic fibrosis."
Pharmaxis Ltd gets approval to sell Bronchitol® in largest market yet, Russia
Entry into the Russian market for Bronchitol is a significant achievement for the company as it looks to expand the drug’s customer base and increase its potential to generate revenue.
Pharmaxis Ltd stands to gain as NASH biotech acquired for US$1.7B
Market activity in the past has already confirmed that the treatment of NASH is one of the hottest areas in biotech and Allergan’s takeover bid for Tobira has only added fuel to the fire.
Pharmaxis Ltd completes first year of new business plan
Progress under the new business model over the 2016 financial year has been substantial. The company finished the financial year with a cash balance of $39 million and net cash usage over the year of $15 million.
Pharmaxis Ltd achieves milestone as it targets the U.S. market
Gary Phillips, CEO, commented: "We are pleased to have attained this significant milestone in such a large undertaking securing more than 400 study participants at 126 sites in 21 countries."
Pharmaxis Ltd targets big pharma at world's largest biotech conference
BIO is the largest global event for the biotech industry with nearly 16,000 industry leaders from 76 countries attending the conference and over 3,400 companies participating in partnering meetings.